Ermanno Gherardi

List of Publications by Year
in descending order

92 papers	12,370 citations	81900 39 h-index	53230 85 g-index
96 all docs	96 docs citations	96 times ranked	10454 citing authors

#	Article	IF	Citations
1	Human Nonalcoholic Steatohepatitis on a Chip. Hepatology Communications, 2021, 5, 217-233.	4.3	42
2	A Novel HGF/SF Receptor (MET) Agonist Transiently Delays the Disease Progression in an Amyotrophic Lateral Sclerosis Mouse Model by Promoting Neuronal Survival and Dampening the Immune Dysregulation. International Journal of Molecular Sciences, 2020, 21, 8542.	4.1	8
3	Inhibition of the MET Kinase Activity and Cell Growth in MET-Addicted Cancer Cells by Bi-Paratopic Linking. Journal of Molecular Biology, 2019, 431, 2020-2039.	4.2	20
4	Generation and characterization of novel recombinant anti-hERG1 scFv antibodies for cancer molecular imaging. Oncotarget, 2018, 9, 34972-34989.	1.8	19
5	Characterization and structural determination of a new anti-MET function-blocking antibody with binding epitope distinct from the ligand binding domain. Scientific Reports, 2017, 7, 9000.	3.3	7
6	Developing Antagonists for the Met-HGF/SF Proteinâ€“Protein Interaction Using a Fragment-Based Approach. Molecular Cancer Therapeutics, 2016, 15, 3-14.	4.1	7
7	Exploring the chemical space of the lysine-binding pocket of the first kringle domain of hepatocyte growth factor/scatter factor (HGF/SF) yields a new class of inhibitors of HGF/SF-MET binding. Chemical Science, 2015, 6, 6147-6157.	7.4	26
8	Crystal structure of an engineered YopM-InlB hybrid protein. BMC Structural Biology, 2014, 14, 12.	2.3	11
9	Michael Stoker 1918â€“2013. Cell, 2013, 155, 493-494.	28.9	0
10	Engineered variants of InlB with an additional leucineâ€rich repeat discriminate between physiologically relevant and packing contacts in crystal structures of the InlB:MET complex. Protein Science, 2012, 21, 1528-1539.	7.6	9
11	Protein Engineered Variants of Hepatocyte Growth Factor/Scatter Factor Promote Proliferation of Primary Human Hepatocytes and in Rodent Liver. Gastroenterology, 2012, 142, 897-906.	1.3	25
12	Establishing Mammalian Production Cell Lines for Structural Biology by Site-Specific Recombination. , 2012, , 265-268.		0
13	Targeting MET in cancer: rationale and progress. Nature Reviews Cancer, 2012, 12, 89-103.	28.4	1,243
14	Non-Agonistic Bivalent Antibodies That Promote c-MET Degradation and Inhibit Tumor Growth and Others Specific for Tumor Related c-MET. PLoS ONE, 2012, 7, e34658.	2.5	28
15	Glycoprotein production for structure analysis with stable, glycosylation mutant CHO cell lines established by fluorescenceâ€activated cell sorting. Protein Science, 2010, 19, 1264-1271.	7.6	15
16	Structural basis for agonism and antagonism of hepatocyte growth factor. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 13264-13269.	7.1	75
17	Coupling growth-factor engineering with nanotechnology for therapeutic angiogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 13608-13613.	7.1	29
18	Ligand-Mediated Dimerization of the Met Receptor Tyrosine Kinase by the Bacterial Invasion Protein InlB. Journal of Molecular Biology, 2010, 395, 522-532.	4.2	43

#	Article	IF	Citations
19	A Novel Multipurpose Monoclonal Antibody for Evaluating Human c-Met Expression in Preclinical and Clinical Settings. Applied Immunohistochemistry and Molecular Morphology, 2009, 17, 57-67.	1.2	38
20	Engineered HGF/SF Variants Promote Angiogenesis. FASEB Journal, 2009, 23, 934.9.	0.5	0
21	X-ray and Neutron Small-Angle Scattering Analysis of the Complex Formed by the Met Receptor and the Listeria monocytogenes Invasion Protein InlB. Journal of Molecular Biology, 2008, 377, 489-500.	4.2	34
22	Engineering the NK1 Fragment of Hepatocyte Growth Factor/Scatter Factor as a MET Receptor Antagonist. Journal of Molecular Biology, 2008, 377, 616-622.	4.2	38
23	Interactions of Hepatocyte Growth Factor/Scatter Factor with Various Glycosaminoglycans Reveal an Important Interplay between the Presence of Iduronate and Sulfate Density. Journal of Biological Chemistry, 2008, 283, 5235-5248.	3.4	80
24	A mechanistic basis for converting a receptor tyrosine kinase agonist to an antagonist. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 14592-14597.	7.1	55
25	Eotaxin-1/CC Chemokine Ligand 11: A Novel Eosinophil Survival Factor Secreted by Human Pulmonary Artery Endothelial Cells. Journal of Immunology, 2007, 179, 1264-1273.	0.8	33
26	Structure of the Human Receptor Tyrosine Kinase Met in Complex with the Listeria Invasion Protein InlB. Cell, 2007, 130, 235-246.	28.9	147
27	Insights into the Structure/Function of Hepatocyte Growth Factor/Scatter Factor from Studies with Individual Domains. Journal of Molecular Biology, 2007, 367, 395-408.	4.2	80
28	Hepatocyte Growth Factor/Scatter Factor and MET Are Involved in Arterial Repair and Atherogenesis. American Journal of Pathology, 2006, 168, 340-348.	3.8	24
29	Structural Basis of Affinity Maturation of the TEPC15/VÎº45.1 Anti-2-phenyl-5-oxazolone Antibodies. Journal of Molecular Biology, 2006, 359, 1161-1169.	4.2	6
30	Signalling by HGF/SF and Met: the role of heparan sulphate co-receptors. Biochemical Society Transactions, 2006, 34, 414-417.	3.4	54
31	Computer-assisted mass spectrometric analysis of naturally occurring and artificially introduced cross-links in proteins and protein complexes. FEBS Journal, 2006, 273, 281-291.	4.7	54
32	Structural basis of hepatocyte growth factor/scatter factor and MET signalling. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 4046-4051.	7.1	193
33	Crystal structure of the Î²-chain of human hepatocyte growth factor-like/macrophage stimulating protein. FEBS Journal, 2005, 272, 5799-5807.	4.7	23
34	The Interactions of Hepatocyte Growth Factor/Scatter Factor and Its NK1 and NK2 Variants with Glycosaminoglycans Using a Modified Gel Mobility Shift Assay. Journal of Biological Chemistry, 2004, 279, 43560-43567.	3.4	52
35	The sema domain. Current Opinion in Structural Biology, 2004, 14, 669-678.	5.7	142
36	Nitric oxide modulates hepatocyte growth factor/scatter factor-induced angiogenesis. Angiogenesis, 2004, 7, 285-294.	7.2	6

#	Article	IF	Citations
37	Diverse and potent activities of HGF/SF in skin wound repair. Journal of Pathology, 2004, 203, 831-838.	4.5	122
38	Aromatic amino acids at the surface of InlB are essential for host cell invasion by Listeria monocytogenes. Molecular Microbiology, 2003, 48, 1525-1536.	2.5	43
39	Met, metastasis, motility and more. Nature Reviews Molecular Cell Biology, 2003, 4, 915-925.	37.0	2,399
40	Targeting of Mitogen-Activated Protein Kinases and Phosphatidylinositol 3 Kinase Inhibits Hepatocyte Growth Factor/Scatter Factorâ€“Induced Angiogenesis. Circulation, 2003, 107, 2955-2961.	1.6	32
41	Hepatocyte Growth Factor/Scatter Factor Can Induce Angiogenesis Independently of Vascular Endothelial Growth Factor. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 69-75.	2.4	126
42	Functional map and domain structure of MET, the product of the c-met protooncogene and receptor for hepatocyte growth factor/scatter factor. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 12039-12044.	7.1	163
43	A G2/M Cell Cycle Block in Transformed Cells by Contact with Normal Neighbours. Cell Cycle, 2003, 2, 482-485.	2.6	10
44	Cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs inhibit hepatocyte growth factor/scatter factor-induced angiogenesis. Cancer Research, 2003, 63, 8351-9.	0.9	16
45	A New Crystal Form of the NK1 Splice Variant of HGF/SF Demonstrates Extensive Hinge Movement and Suggests That the NK1 Dimer Originates by Domain Swapping. Journal of Molecular Biology, 2002, 319, 283-288.	4.2	22
46	Crystal structures of NK1-heparin complexes reveal the basis for NK1 activity and enable engineering of potent agonists of the MET receptor. EMBO Journal, 2001, 20, 5543-5555.	7.8	107
47	Involvement of hepatocyte growth factor/scatter factor and Met receptor signaling in hair follicle morphogenesis and cycling. FASEB Journal, 2000, 14, 319-332.	0.5	129
48	Heparan Sulfate-modified CD44 Promotes Hepatocyte Growth Factor/Scatter Factor-induced Signal Transduction through the Receptor Tyrosine Kinase c-Met. Journal of Biological Chemistry, 1999, 274, 6499-6506.	3.4	198
49	Crystal structure of the NK1 fragment of HGF/SF suggests a novel mode for growth factor dimerization and receptor binding. Nature Structural Biology, 1999, 6, 72-79.	9.7	110
50	Expression of a Cx43 Deletion Mutant in 3T3 A31 Fibroblasts Prevents PDGF-Induced Inhibition of Cell Communication and Suppresses Cell Growth. Experimental Cell Research, 1999, 249, 367-376.	2.6	32
51	The effect of high-frequency random mutagenesis on in vitro protein evolution: a study on TEM-1 Î²-lactamase 1 1Edited by A. R. Fersht. Journal of Molecular Biology, 1999, 285, 775-783.	4.2	192
52	Engineered mutants of HGF/SF with reduced binding to heparan sulphate proteoglycans, decreased clearance and enhanced activity in vivo. Current Biology, 1998, 8, 125-135.	3.9	91
53	Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase. Trends in Cell Biology, 1998, 8, 404-410.	7.9	558
54	Insights into the structure of hepatocyte growth factor/scatter factor (HGF/SF) and implications for receptor activation. FEBS Letters, 1998, 430, 126-129.	2.8	29

#	Article	IF	Citations
55	Dimerization of Fab fragments enables ready screening of phage antibodies that affect hepatocyte growth factor/scatter factor activity on target cells. European Journal of Immunology, 1997, 27, 618-623.	2.9	10
56	Evolution of Plasminogenâ€Related Growth Factors (HGF/SF and HGF1/MSP). Novartis Foundation Symposium, 1997, 212, 24-45.	1.1	8
57	Domain Structure of Hepatocyte Growth Factor/Scatter Factor (HGF/SF). Novartis Foundation Symposium, 1997, 212, 84-104.	1.1	0
58	An Approach to Random Mutagenesis of DNA Using Mixtures of Triphosphate Derivatives of Nucleoside Analogues. Journal of Molecular Biology, 1996, 255, 589-603.	4.2	300
59	Co-expression of theHGF/SF andc-met genes during early mouse embryogenesis precedes reciprocal expression in adjacent tissues during organogenesis. , 1996, 18, 254-266.		98
60	Expression of HGF/SF, HGFI/MSP, and c-met suggests new functions during early chick development. Genesis, 1995, 17, 90-101.	2.1	84
61	Scatter factor/hepatocyte growth factor is essential for liver development. Nature, 1995, 373, 699-702.	27.8	1,354
62	Roles of hepatocyte growth factor/scatter factor and the met receptor in the early development of the metanephros.. Journal of Cell Biology, 1995, 128, 171-184.	5.2	308
63	Characterization of the Scatter Factor/Hepatocyte Growth Factor Gene Promoter. Journal of Biological Chemistry, 1995, 270, 830-836.	3.4	36
64	HGF/SF Inhibits Junctional Communication. Experimental Cell Research, 1995, 219, 657-663.	2.6	38
65	Universal cloning and direct sequencing of rearranged antibody V genes using C region primers, biotin-captured cDNA and one-side PCR. Journal of Immunological Methods, 1995, 178, 241-251.	1.4	19
66	Towards a molecular understanding of neural induction. Biology of the Cell, 1995, 84, 90-90.	2.0	0
67	Molecular evolution and domain structure of plasminogenâ€related growth factors (HGF/SF and) Tj ETQq1 1 0.784314 rgBT /Overloc	7.6	166
68	Topography of apolipoprotein B in subcellular fractions from rabbit liver. Biochemical Society Transactions, 1993, 21, 126S-126S.	3.4	0
69	Transforming growth factor-Î²1 and interleukin-1Î² stimulate LDL receptor activity in Hep G2 cells. Atherosclerosis, 1992, 97, 21-28.	0.8	27
70	Membrane-bound apolipoprotein B is exposed at the cytosolic surface of liver microsomes. FEBS Letters, 1992, 304, 24-26.	2.8	14
71	Structural repertoire of the human VH segments. Journal of Molecular Biology, 1992, 227, 799-817.	4.2	412
72	Original and artificial antibodies. Nature, 1992, 357, 201-202.	27.8	66

#	Article	IF	Citations
73	Non-random features of the repertoire expressed by the members of one Vx gene family and of the V-J recombination. European Journal of Immunology, 1992, 22, 1627-1634.	2.9	42
74	A sensitive RNase protection assay for the quantitation of the mRNAs for the LDL receptor and HMG-CoA reductase in human total RNA Effects of treatments on cells in culture designed to up- and down-regulate expression of the LDL receptor. Atherosclerosis, 1991, 90, 81-90.	0.8	10
75	Growth factors and cell movement. European Journal of Cancer & Clinical Oncology, 1991, 27, 403-405.	0.7	24
76	Colony assays for antibody fragments expressed in bacteria. Journal of Immunological Methods, 1991, 139, 197-205.	1.4	42
77	Regulation of cell movement: the motogenic cytokines. Biochimica Et Biophysica Acta: Reviews on Cancer, 1991, 1072, 81-102.	7.4	89
78	Mutation and selection during the secondary response to 2-phenyloxazolone.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 5508-5512.	7.1	66
79	Purification and characterization of scatter factor. Exs, 1991, 59, 53-62.	1.4	4
80	The distribution of apolipoprotein B in endoplasmic reticulum and Golgi subfractions of rabbit liver. Biochemical Society Transactions, 1990, 18, 1181-1181.	3.4	2
81	Hepatocytes and scatter factor. Nature, 1990, 346, 228-228.	27.8	219
82	A single-step procedure for cloning and selection of antibody-secreting hybridomas. Journal of Immunological Methods, 1990, 126, 61-68.	1.4	21
83	Scatter factor and other regulators of cell mobility. British Medical Bulletin, 1989, 45, 481-491.	6.9	18
84	Purification of scatter factor, a fibroblast-derived basic protein that modulates epithelial interactions and movement.. Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 5844-5848.	7.1	390
85	Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature, 1987, 327, 239-242.	27.8	1,300
86	Factors Affecting Epithelial Interactions. Novartis Foundation Symposium, 1987, 125, 217-239.	1.1	9
87	Plasma and urine lipoproteins during the development of nephrotic syndrome induced in the rat by adriamycin. Experimental and Molecular Pathology, 1983, 39, 282-299.	2.1	20
88	Experimental nephrotic syndrome in the rat induced by puromycin aminonucleoside. Plasma and urinary lipoproteins. Experimental and Molecular Pathology, 1980, 32, 128-142.	2.1	59
89	Experimental nephrotic syndrome induced in the rat by puromycin aminonucleoside: Hepatic synthesis of neutral lipids and phospholipids from3H-water and3H-palmitate. Lipids, 1980, 15, 108-112.	1.7	26
90	Experimental nephrotic syndrome in the rat induced by puromycin aminonucleoside: Hepatic synthesis of lipoproteins and apolipoproteins. Lipids, 1980, 15, 858-863.	1.7	19

#	Article	IF	Citations
91	Chemical and morphological changes of rat plasma lipoproteins after a prolonged administration of diets containing olive oil and cholesterol. Atherosclerosis, 1977, 28, 369-387.	0.8	18
92	Chairman's Summing-Up. Novartis Foundation Symposium, 0, , 252-253.	1.1	0